Compare Viatris Inc (VTRS) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Williams-Sonoma, Inc. — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| VTRS | WSM | |
|---|---|---|
Market Cap | $19.09B | $26.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.86 | $251.81 |
52-Week Low | $9.49 | $168.64 |
Enterprise Value | $31.21B | $27.33B |
Dividend Yield | 2.89% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $2.10 exceeding expectations. Revenue growth of 6.2% in Q2 2026 reflects market share gains in a flat home furnishings industry, supported by a robust net income margin of 14.73% and ROE of 54.96%.
The outlook is positive given raised full-year guidance and analyst consensus price target of $252.62, though near-term risks include tariff pressures on margins and technical resistance near $231. Institutional buying, such as HSBC's 12.1% stake increase in Q2 2026, underscores confidence in continued execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
